ArticleFrontiers in oncology2026
Expression of estrogen receptor and progesterone receptor in endometrial cancer and their correlations with clinicopathological features.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To investigate the expression levels of estrogen receptor (ER) and progesterone receptor (PR) in endometrial carcinoma (EC) and their correlations with standardized clinicopathological parameters in a single-center surgical cohort. Methods: Retrospective clinical and pathological data of 78 EC patients receiving primary surgery at the Department of Obstetrics and Gynecology of Kiang Wu Hospital between Jan 2016 and Aug 2022 were collected. ER/PR expression was quantified via immunohistochemistry (IHC) using the Allred scoring system. Dichotomous receptor positivity (Allred 0-2 negative/3-8 positive) and continuous total Allred scores were analyzed separately. Fisher's exact test or χ² test was used for categorical comparison; Kruskal-Wallis H test with adjusted Results: The overall cohort included 71 endometrioid carcinoma (EC) and 7 non-endometrioid carcinoma (NEC) cases. ER and PR positive rates were significantly higher in endometrioid lesions (97.2% and 94.4%) than non-endometrioid subtypes (57.1% for both, P = 0.018/P = 0.018). Continuous Allred scores of ER and PR declined significantly with worsening tumor differentiation (all adjusted P<0.05). For FIGO staging, significantly reduced ER and PR Allred scores were observed in Stage II compared with Stage I. The single Stage-III case was reported descriptively and was not included in formal statistical testing. Patients with lymph node metastasis exhibited lower PR Allred scores (P = 0.021), while ER expression showed no statistically significant difference (P = 0.076). No significant associations were found between ER/PR scores and depth of myometrial invasion or lymphovascular space invasion (LVSI) (all P>0.05). Conclusion: Reduced ER and PR expression correlates with poorer tumor differentiation and advanced FIGO stage in endometrioid endometrial carcinoma; PR loss is independently associated with lymph node metastasis. This study only identifies crude cross-sectional correlations without survival or multivariable adjustment data, so ER/PR may merely serve as auxiliary morphological markers reflecting tumor aggressive potential, rather than standalone indicators for prognosis or individualized hormone therapy guidance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.